A Phase 3 clinical trial evaluating Pfizer’s (NYSE:PFE) neuropathic pain med Lyrica (pregabalin) for the adjunctive treatment of primary generalized tonic-clonic seizures (also known as grand mal seizures that involve the entire body) failed to sufficiently separate from placebo. Specifically, there was not a statistically significant reduction in the 28-day seizure rate in the treatment group versus control over a period of 21 weeks.
No new safety signals were observed.
The company conducted the study under its post-marketing commitment with the FDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.